Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McGill University

$100,000.00

Pharmacological chaperones for F508del-CFTR and their mechanisms of action.

FY 2016-17

Summary
Proteins play vital roles in many diseases. Misfolded proteins are often mislocalized and degraded, but they can still function if they reach their normal cellular location. In the protein trafficking disease, cystic fibrosis, the mutant protein F508delCFTR is recognized by the cell's quality control systems and retained in an incorrect location. Drugs that partially restore the delivery and function of CFTR have been developed, but they provide only a small benefit for most patients and more effective drugs are needed. We have identified new compounds that bind directly to CFTR and correct its trafficking, but to improve them enough to become drugs we need to answer questions such as "Where do they bind? Do different drugs bind at different sites? How do they work together to correct trafficking? Which combinations of correctors will give the most benefit to patients?" This proposal addresses these questions with a view to developing better therapies for CF and protein trafficking diseases generally.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
366639
Name
Hanrahan John W
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Pharmacological chaperones for F508del-CFTR and their mechanisms of action.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Bronchial Epithelial Cells; Cystic Fibrosis; Drug Synergy; Endoplasmc Reticulum; Ion Channels; Mechanism Of Action; Pharmacological Chaperones; Protein Interactions; Protein Trafficking Diseases; Translational Research
Abstract
Proteins play vital roles in many diseases. Misfolded proteins are often mislocalized and degraded, but they can still function if they reach their normal cellular location. In the protein trafficking disease, cystic fibrosis, the mutant protein F508delCFTR is recognized by the cell's quality control systems and retained in an incorrect location. Drugs that partially restore the delivery and function of CFTR have been developed, but they provide only a small benefit for most patients and more effective drugs are needed. We have identified new compounds that bind directly to CFTR and correct its trafficking, but to improve them enough to become drugs we need to answer questions such as "Where do they bind? Do different drugs bind at different sites? How do they work together to correct trafficking? Which combinations of correctors will give the most benefit to patients?" This proposal addresses these questions with a view to developing better therapies for CF and protein trafficking diseases generally.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hanrahan, John W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~